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1. Introduction 
In many countries, diabetic renal disease has become, or will soon become, the single most 
common cause of end-stage renal disease (ESRD). End stage renal failure (ESRF) in type 2 
diabetic patients is increasing worldwide (1).  
Diabetic nephropathy (DN) is the most prevalent cause of ESRD in the USA. The proportion 
of ESRD patients who are diabetic is increasing by more than 1% each year in the USA. The 
rate of admission of uraemic patients with diabetes as a co-morbid condition in the USA was 
107 per million population (p.m.p.) per year in 1994 (2) and is currently approximately 120 
p.m.p. The corresponding figures in other countries are lower: 66 p.m.p. in Japan and 52 
p.m.p. in southwestern Germany (1). The incidence of ESRD in Europe due to diabetes, 
hypertension and renal vascular disease has nearly doubled over 10 years; in 1998–99, it 
varied between countries from 10.2 to 39.3 p.m.p. for diabetes, from 5.8 to 21.0 for 
hypertension, and from 1.0 to 15.5 for renal vascular disease (3). The figures are lower in the 
Mediterranean countries, as well as in Macedonia (4), although an increase has recently been 
reported from Spain (5) and Italy (6). ESRD and ESRF caused by DN was 10%, 5–15% in 
different haemodialysis 
Centres for adults in 2000 in the Republic of Macedonia (4), as well as 22% in 2006 (4a).  
The great majority of diabetic patients admitted suffer from type 2 diabetes. 
The increasing trend may be explained by a number of factors: 
1. the increasing prevalence of type II diabetes in the general population; 
2. improved survival of diabetic patients, particularly diabetic patients with nephropathy, 
because of better treatment of hypertension and coronary heart disease, so that they live 
long enough to experience renal failure; 
3. less restriction of admission to renal replacement therapy. 
One major problem continues to be late referral. 
The poor prognosis of patients with diabetic nephropathy is well known in both in type 1 
and type 2 diabetes. The high mortality and morbidity, especially in type 2 diabetic patients 
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with nephropathy, are mainly caused by coronary artery, cerebrovascular and peripheral 
vascular disease (7). 
The survival of type 1 diabetic patients requiring renal replacement therapy has been 
dramatically improved during the last decade; however, prognosis for type 2 diabetic 
patients with ESRD continues to be extremely poor (1). 
2. Evaluation of the diabetic patient with preterminal renal failure 
Evaluation of the diabetic patients with preterminal renal failure has the following aims: 
1. to assess the course of renal failure (progression); 
2. to recognize the presence of acute renal failure, or acute or chronic renal failure; 
3. to recognize renal problems other than diabetic nephropathy, for example ischaemic 
nephropathy, diabetic cystopathy, urinary tract infection; 
4. to monitor the patient for clinical evidence of extrarenal microvascular and 
macrovascular complications, for example retinopathy or polyneuropathy and coronary 
heart disease or arterioocclusive disease. 
Some of these coincident kidney diseases are listed below. 
2.1 Ischaemic renal disease 
Renal ischaemia or atherosclerotic renal artery stenosis is much more common in diabetics 
than previously assumed (8). In this case one should be cautious regarding ACE-inhibitors 
or angiotensin receptor blocking antihypertensives. Frequent control of s-creatinin, s-
potassium and bodyweight are mandatory. A two-fold increase in s-creatinine should 
prompt the physician to stop this type of medication. 
2.2 Urinary tract infection 
Urinary tract infection (UTI) has frequently led to renal parenchymatous infection with 
purulent papillary necrosis and intrarenal abscess formation. UTI may be frequent in 
diabetics, especially when residual urine is present.  
2.3 Glomerulonephritis 
Glomerulonephritis (GN), particularly membranous GN, is thought to be more frequent in 
diabetics, but this has not been supported by other studies. 
2.4 Acute renal failure 
Diabetic patients with nephropathy are exceptionally susceptible to acute renal failure (ARF) 
after the administration of radiocontrast media, the risk being similar with ionic and non-
ionic materials. The risk may be reduced by fluid administration and a temporary withdrawal 
of diuretics. In patients with severely elevated serum-creatinine a dialysis procedure 
immediately after the radiographic procedure is warranted, without any delay in time.  
Hydroxyethyl starch and ACE inhibitors also cause deterioration of renal function in 
diabetic patients, especially in those with congestive heart failure. 
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The points relating to treatment strategies and decision-making in diabetic patients with 
renal failure present are: evaluation (and treatment) of risk factors for progression, 
monitoring of progression, evaluation of patient for renal replacement therapy (dialysis, 
transplantation), informing patient both and care about renal replacement therapy, 
preparing patients for renal replacement therapy (vascular access, check-up for 
transplantation) and adjustment of diet and insulin or oral hypoglycaemic agents. 
In the table 1 is a check-list for management of diabetic patients with preterminal renal 
failure. 
 
• Reversible causes of renal failure present? (contrast media, urinary tract infection, 
angiotensin converting enzyme inhibitors, congestive heart failure) 
• Hypovolaemia present? 
• Coronary heart disease present (percutaneous transluminal angioplasty or coronary 
bypass surgery required? 
• Cardiomyopathy or congestive heart failure present? 
• Congestion due to hypervolaemia or heart failure? 
• Early vascular access? 
• Hypoglycemic episodes present? Adequate nutrient intake? 
• Eye (examined and treated?) 
• Foot (neuropathic? ischaemic? foot ulcers? infection?) 
• Residual urine present, urinary tract infection? 
• Normotension or antihypertensive treatment achieved? 
• Orthostatic blood pressure drop? 
• Gastroparesis or diarrhoeal episodes? 
Table 1. Check-list for management of diabetic patients with preterminal renal failure 
3. Option in uremia therapy 
Determination of which treatment option is "best" for a particular diabetic ESRD patient, 
however, is an individualized judgment (table 2) depending on the patient's age, education, 
geographic location, family and social support systems, and the extent of co-morbid 
conditions, most importantly, of cardiovascular integrity. Major subjects which must be 
apprised when devising a longterm plan for ESRD management include anticipated patient 
compliance and potential to participate in self-treatment. Each ESRD treatment option must 
be explained in understandable terms covering the probable survival rate, the degree of 
rehabilitation and the expected stabilisation of extrarenal diabetics complications. Ideally, 
what has been termed a "life plan" should be constructed for every ESRD patient after 
consultation between the health care team, the patient, and the members of the patient's 
social support system. 
While the best rehabilitation of diabetic ESRD patients is achieved in recipients of living 
related donor renal transplants, this superior outcome may reflect a selection bias in which 
younger, healthier patients are chosen for a transplant leaving a residual pool of more 
morbid dialysis patients. Morbidity from blindness and neuropathy (but not coronary artery 
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or peripheral vascular disease) is decreased in diabetic kidney transplant recipients (9). 
Lacking randomized prospective trials of diabetics treated with dialytic therapy versus a 
kidney transplant, controlled for age, race, gender, and severity of extrarenal complication, 
caution must be exercised when assessing one ESRD therapy against another. A reasonable 
policy can be based on the premise that while the best rehabilitation is effected by renal 
transplantation, there is no distinctly superior treatment for the uraemic diabetic, and 
therefore, assessment and treatment of diabetic with ESRD must be highly individualized 
(10). 
 
1. Passive suicide which is the consequence of declining dialysis or kidney 
transplantation 
2. Haemodialysis 
- Facility haemodialysis 
- Home haemodialysis 
3. Peritoneal dialysis 
- Intermittent peritoneal dialysis (IPD) 
- Continuous ambulatory peritoneal dialysis (CAPD) 
- Continuous cyclic peritoneal dialysis (CCPD) 
4. Renal transplantation 
- Cadaver donor kidney 
- Living donor kidney 
5. Pancreas, plus kidney transplantation 
- IDDM 
- ? NIDDM 
- islet-cell transplantation (type 1) 
Table 2. Options in uremia therapy for diabetic ESRD patients 
4. Timing the start of dialytic therapy 
As residual creatinine clearance falls to about 20–30 ml/min, available ESRD options should 
be discussed and a selection made. In practice, bias by the patient's most trusted physician 
usually is the major factor determining which renal replacement therapy is chosen. 
Diabetic complications which persist and/or progress during ESRD and on dialysis are: 
retinopathy, glaucoma, cataracts; coronary artery disease, cardiomyopathy; cerebrovascular 
disease; hypertension; peripheral vascular disease: limb amputation; motor neuropathy, 
sensory neuropathy; autonomic dysfunction: diarrhoea, constipation, hypotension; 
myopathy; depression; infections; bladder neuropathy; sexual disorders; impotence; eating 
disorders; gastroparesis with vomiting and food retention; alteration in the metabolic 
control and dyslipidaemias; ion imbalance and metabolic acidosis. 
For the 80% of uraemic diabetic selecting haemodialysis (HD), the construction of a vascular 
access is of great importance. Once it is clear that uraemia is a near term probability (less 
than one year), an arteriovenous access should be constructed. 
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The first choice in HD access in diabetics is an autologous a-v fistula of the Cimino-Brescia 
type. 
When peritoneal dialysis (PD) is selected advance planning should ensure that a suitable 
peritoneal catheter is in situ 2–4 weeks before starting dialysis.  
Option for a kidney or a kidney plus pancreas transplant obviously demands referral to and 
evaluation by a transplant team. In the case of an intended living related donor transplant, 
interim dialysis can be avoided by proper planning, performing the transplant at an early 
stage of uraemic symptoms. A long wait is usual for a cadaver kidney. 
Accordingly, patients should be entered on waiting lists when the creatinin clearance is 
about 10–15 ml/min. 
5. Haemodialysis in diabetics 
Haemodialysis has emerged as the most common treatment for all forms of renal failure 
including diabetic nephropathy. It is generally accepted that renal replacement therapy 
should be considered as a creatinine clearance of approximately 9–14 ml/min in non-
diabetic uraemia patients (11). 
In diabetic patients with ESRD, dialysis is started at creatinine clearance as high as 15–20 
ml/min, at serum creatinine levels as low as 3–5 mg/dl. 
In any case, HD should be started before the clinical status deteriorates, secondary to fluid 
overload, malnutrition, hyperkalaemia and infection. This is usually the case when the GFR 
declines below 20 ml/min. 
Vascular access surgery (usually autologous arteriovenous fistula of the Cimino-Brescia 
type) some month before the initiation of the dialysis treatment helps to avoid central 
venous lines and their concomitant complications. Blood drawing for regular serum 
chemistry is restricted to the dorsal hand veins only. 
5.1 Prognosis in patients with diabetic nephropathy on haemodialysis and in 
assessing the adequacy of haemodialysis 
In the past, the prognosis for DN was discouraging, with 77% of patients dying within 10 
years after the onset of persistent proteinuria. The survival of dialysed diabetics has 
improved over the past decade. No single factor is credited with reducing the death rate 
of haemodialysed diabetics, though better control of hypertension, a reduction in 
intravascular volume overload, better nutrition, and better vascular access surgery have 
contributed. 
Table 3 compares actuarial 5-year survival of non-diabetic and diabetic patients on 
maintenance haemodialysis in different countries. It is obvious that in countries with a low 
prevalence of cardiovascular deaths in the general population, e.g. East Asian countries and, 
to a lesser extent, the Mediterranean countries, survival of diabetic patients on RRT is 
significantly better than that in countries with notoriously high cardiovascular death rates, 
e.g. USA and Germany. 
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 No diabetes Diabetes 
Australia 60 42/27 a 
Japan b 64/73 50/40 
Taiwan 65 37 
Hong Kong 70 20 
Italy (Lombardy) 61 28 
Spain (Catalonia) c 65 30 
Germany – 38/5 
USA d 35 21 
Values are expressed as percentage of surviving patients. 
a Reported as type 1 / type 2 diabetes. 
b Reported as haemodialysis / continuous ambulatory peritoneal dialysis. 
c Includes renal transplantation. 
d Censored at first transplantation. 
Table 3. Comparison of actuarial 5 year survival of non-diabetic and diabetic patients on 
dialysis treatment in different countries (1). 
In table 4 are the causes of death in diabetic patients on HD. 
 
 
Type 1 diabetes 
(n = 67)
Type 2 diabetes 
(n = 129)
Myocardial infarction  8 12 
Sudden death  7 13 
Cardiac other 3 17 
Stroke 0 6 
Septicaemia 7 11 
Interruption of treatment 2 8 
Other 2 13 
Total 29 (40%) 80 (43%) 
Total cardiovascular mortality was 62% in type 1 and 60% in type 2 diabetes. 
Table 4. Causes of death in diabetic patients 57 months after start of haemodialysis (12). 
Cardiovascular disease and serious infections are the major causes of death in 
haemodialysed and transplanted diabetics. Despite recent improvement, rehabilitation of 
haemodialysed diabetics continues to be inferior to that of nondiabetics. Improvement of 
survival is a matter of reduction of cardiovascular death and infection. 
5.2 Cardiovascular death and adequacy of dialysis 
Cardiac death is strongly predicted by a history of vascular disease (peripheral vascular 
and/or carotid), myocardial infarction and angina pectoris. Proliferative retinopathy and 
polyneuropathy were associated with an increased cardiac risk, in the latter possibly due to an 
imbalance of autonomic cardiac innervation. Hypotensive cardiac episodes during dialysis are 
also predictive of cardiac death. 
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Haemodialysis procedures should be with low ultrafiltration rates and prolonged duration 
of dialysis sessions (13). In practice, ultrafiltration in diabetics should not exceed more than 
500–600 ml/h on haemodialysis. This means dialysis sessions of more than 4h and, in larger 
patients, of more than 5h haemodialysis three times per week. 
Guidelines have been created to assure adequate dialysis – "dose of dialysis". 
According to DOQI (Dialysis Outcomes Quality Initiative), a Kt/V (indicator for adequacy of 
dialysis, where K is the dialyser clearance rate, t the net duration of dialysis and V the 
corrected body volume) of above 1.2 (e.g. a 70-kg patient dialysed for 5h) is adequate (14). 
Lower Kt/V, especially below 1, is associated with a higher mortality rate and this is 
particularly true of the patient with diabetic nephropathy. 
Optimal dialysis in diabetic patients: 
Need for a dialysis technique which will provide 
- – absence of acetate 
- – good cardiovascular stability 
- – good acid-base correction 
- – good solute removal 
- – good biocompatibility 
5.3 Special problems of diabetic patients on haemodialysis 
5.3.1 Vascular access 
In a diabetic patient it is often more difficult to establish vascular access because of a poor 
arterial inflow (atherosclerosis, media calcification of the artery) and venous run-off 
(hypoplasia or thrombosed veins) in chronically ill patients, with numerous stays in 
hospital. Arterio-venous anastomosis should be placed in the upper forearm to maintain 
adequate shunt blood flow. It is therefore advisable to establish vascular access early, 
when creatinine clearance is above 20-25 ml/min (14, 15). In malnourished, older 
individuals, this level of GFR impairment can be reached even at a serum-creatinine of 
2 mg/dl. 
One should patiently wait for maturing of the fistula: early puncture tends to be associated 
with haematoma formation, scarring, stenosis and thrombosis, and should be avoided, even 
if dialysis has to be performed by a central venous catheter. Some authors have reported 
poor functioning of the vascular access in diabetics, with only 64% of fistula functioning 
after 1 year compared to 83% in non-diabetic. 
Radial steal syndrome, venous hypertension, infection/thrombosis (15, 16), and ischaemic 
monomelic neuropathy could be problems related to vascular access. 
5.3.2 Metabolic control 
In clinical practice, the need for insulin decreases upon the institution of maintenance HD. 
The fall in insulin requirements in no way signifies any improvement in the underlying 
disease. Also, good glucose control should remain a goal even after initiation of dialysis. It 
remains important to protect further injury to other organs such as the eyes. Glycaemic 
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control may also be important for preserving residual renal function for as long as possible 
(17). 
Most nephrologists prefer to dialyse against glucose (200 mg/dl) to achieve better 
stabilization of plasma glucose concentrations. One must consider, however, that glucose-
containing dialysate does not guarantee normoglycaemia if the prescribed insulin dose is 
too high (18,19). "Tight" metabolic control – a key component in diabetic management – 
risks potentially fatal hypoglycaemic episodes in haemodialysed patients (14). Oral 
sulphonylurea must be avoided, in fact is strictly forbidden, because of prolonged 
hypoglycaemia in endstage renal failure (20). 
If glucose-free dialysate is used, glucose loss (amounting to 80-100 g per dialysis session) 
may occur. It has been argued that the glucose loss into the dialysate contributes to 
catabolism but no convincing evidence for this was produced in a control trial (20). 
Diabetic control is occasionally rendered difficult by diabetic gastroparesis and the tendency 
of gastric motility to deteriorate acutely during dialysis sessions. 
Adequate control of glycaemia is important: hyperglycaemia causes intense thirst and 
subsequent increased fluid intake, as well as osmotic water shift and shift of potassium from 
the intracellular to the extracellular space, with the attendant risk of circulatory and 
pulmonary congestion and hyperkalaemia. 
Poorly controlled diabetics are also more susceptible to infection. 
The HbA1c should be < 8.0% (18, 19, 22). 
5.3.3 Intradialytic and interdialytic blood pressure 
Blood pressure in the diabetic is primarily volume-dependent. Consequently, hypertension 
tends to be more common in dialysed diabetics, who have higher predialytic blood 
pressures, require multidrug therapy more often than non-diabetic uraemic patients. About 
one-half of haemodialysed diabetics require antihypertensive medications, compared to 
27.7% of non-diabetics (23). Betablockers should not be used in diabetics as they exacerbate 
hypertriglyceridemia, worsen glucose control and mask symptoms of severe 
hypoglycaemia. Improvement is typical in volumen-dependent hypertension after 
intradialytic fluid extraction. The problem is compounded by the fact that intradialytic 
hypotension is more frequent in diabetics; as a consequence it is often difficult to reach the target 
dry weight. 
Hypotension is more prevalent in diabetic than in non-diabetic haemodialysis patients. 
Episodic hypotension is at least 20% greater in incidence while nausea and vomiting are 
three times more prevalent (23). Episodes of hypotension are highly predictive of cardiac 
death (24). Severe or sustained hypotension may precipitate angina pectoris culminating in 
acute myocardial infarction. 
Intradialytic hypotension is a multi-factorial problem; inadequate circulatory adjustment to 
volume subtraction (as a consequence of autonomous polyneuropathy) and left ventricular 
diastolic malfunction (necessitating higher left ventricular filling pressures) have both been 
implicated in its genesis. 
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Hypotensive episodes have been associated with an increased risk of sudden cardiac death, 
acute myocardial ischaemia, deterioration of maculopathy and non-thrombotic mesenteric 
ischaemia. 
The following suggestions could be useful for minimizing haemodialysis-induced 
hypotension in diabetics (9): 
• bicarbonate rather than acetate dialysate, 
• acetate free biofiltration, 
• high sodium concentration (140–145 mmol/l) in dialysate, 
• slow rate of ultrafiltration, 
• schedule sequential ultrafiltration and dialysis in patients who are grossly 
• oedematous, 
• prime dialysis circuit with hypertonic albumin solution, 
• maintain hematocrit at or above 30 vol% with erythropoietin, 
• omit antihypertensive medications on morning of dialysis, 
• leg toning exercises to improve venous return, and 
• decrease dialysate temperature (particularly near conclusion of treatment). 
High interdialytic weight gain. Diabetics gain near 30% more weight between haemodialysis 
than non-diabetics. 
Intensified metabolic control facilitated by dietary counselling plus sodium modeling of 
dialysis, and sequential ultrafiltration curtails weight swings and their deleterious 
consequences. 
5.3.4 Lipid abnormalities in diabetic patients with renal failure 
Hypercholesterolaemia and hypertriglyceridaemia are strong predictors of coronary heart 
disease (25). Major dyslipidaemia is seen only in untreated type-1 diabetic patients. A strong 
correlation exists between HbA1c and plasma cholesterol, triglyceride and high-density 
lipoproteins (26). In type-2 diabetes, dyslipidaemia persists even when glycosaemia is well 
controlled, presumably due to an underlying genetic defect which predisposes to both 
diabetes and disturbed lipid metabolism (27, 28). 
In a prospective study (29), a relationship between coronary risk and cholesterol 
concentrations in diabetics admitted for haemodialysis has been established. 
Non-accumulating fibrates or HMG Co-reductase inhibitors are indicated for the treatment 
of dyslipidaemia which does not respond to dietary manipulation. Regular control of 
creatinin kinase (rhabdomyolysis) is recommended. 
5.3.5 Erythropoietin and iron substitution in uraemic diabetic patients 
Len venticular hypertrophy (LVH) is more prevalent in diabetics compared to non-diabetics 
with end-stage renal disease, and it is possible that the beneficial effects of erythropoietin on 
LVH could be particularly relevant for diabetic patients (30, 31). 
Currently, there is no reason to recommend a different target haemoglobin for diabetic and non-
diabetic patients; a haemoglobin of 11–12 g/dl is therefore also appropriate for diabetic patients. 
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Increases in blood pressure, vascular access clotting and even seizures have been observed 
more frequently in diabetic dialysis patients when haemoglobin was increased too rapidly. 
A suggested mode of correction of anaemia in diabetic patients is as follows: a cautious 
dosage of erythropoietin (initial dose of 2000 three times weekly s.c., followed by increments 
of 2000 at monthly intervals) and careful adjustment of heparinisation during dialysis. If 
haemoglobin increases by > 1.3 g/dl over two weeks, the erythropoietin dose should be 
reduced. Once the target haemoglobin has been reached, the weekly dosage should be 
reduced and haemoglobin monitored at regular intervals. 
It is important to establish adequate iron substitution in erythropoietin treated dialysed 
diabetic patients. In clinical practice intravenous iron substitution, at the end of the dialysis 
procedure, is safe and effective. A target ferritin level of above 250 mg/dl is advisable. 
During infection episodes, however, iron substitution should be temporarily stopped. 
5.4 Malnutrition in dialysis – dependent diabetics 
It is important that diabetic patients on dialysis maintain adequate energy (35–40 
kcal/kg/day). In addition, protein intake should not be below 1.3 g/kg a day because of the 
known higher protein requirements of dialysis patients. Anorexia and prolonged 
habituation to dietary restrictions are important reasons for malnutrition of the diabetic 
patient on dialysis. Malnutrition is a common concern in dialysed diabetic patients. 
5.5 Infections in uraemic diabetic patients 
Bacterial infections are common complications in uraemic diabetic patients (32), in whom 
the polymorphnuclear leukocyte function is depressed, particularly when acidosis is 
present. Leukocyte adherence, chemotaxis and phagocytosis may be affected. 
Uraemic diabetics have several particular sites where infections can occur: arteriovenous 
fistula and central venous catheters, CAPD catheter, the urinary tract, the sinus and diabetic 
foot ulcer. Infections of the dialysis access, either HD or CAPD, are mostly caused by 
Staphylococcus as a result of increased skin and mucosal colonization with these organisms 
and need specific therapy. Diabetic patients with prolonged hospital stay should be 
screened for methicillinresistant Staphylococcus. Diabetics are more prone to urinary tract 
infections due to diminishing residual diuresis, incomplete bladder emptying because of 
autonomic neuropathy and following diagnostic or therapeutical instrumentation of the 
urethra or bladder. Foot ulcer infections often progress to septic gangrene and amputation. 
6. Microvascular complications 
6.1 Diabetic retinopathy 
Diabetic retinopathy occurs in 97% of uraemic diabetic patients and 25–30% are blind (33). 
Visual loss results from proliferative retinopathy, cataracts, glaucoma,or vitreous 
haemorrhage. 
Diabetic uraemic patients need regular ophthalmologic controls at a frequency of 3–6 
months. Laser photocoagulation and other intervention are very frequent in all diabetics 
either prior to or during treatment for ESRD. 
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Anticoagulation (heparin) during the haemodialysis procedure and the application of 
platelet aggregation inhibitors (e.g. aspirin) can cause severe retinal bleeding and blindness. 
6.2 Diabetic neuropathy 
Many patients suffer from the consequences of a peripheral sensorimotor neuropathy, or 
from gastroparesis or other bowel disturbances caused by autonomic neuropathy. 
These are very difficult to treat and respond poorly to conventional treatments. Neuropathy is 
less likely to progress in a renal transplant recipient. It also tends to be less severe in patients 
treated with PD, theoretically because of improved clearance of medium-sized molecules (33). 
Many patients may also suffer from impotence caused by neuropathy, vascular disease, or 
medication. These patients may require specialist investigation and treatment. 
7. Macrovascular complication 
7.1 Peripheral vascular disease 
Problems related to the diabetic foot are a major cause of hospital admission, and 50–70% of 
all nontraumatic amputations occur in diabetics. One UK study reported that 6.8% of 
diabetics receiving renal replacement therapy had a major amputation (34, 35). 
There is no reported difference between CAPD and HD (34). The major contributory 
etiologic factors in diabetic foot problems are peripheral vascular disease, diabetic 
neuropathy and stress caused by inappropriate footwear. 
To prevent diabetic foot complications, patients at risk, should be identified should perform 
education about foot care, have regular examination of the feet at clinic, provision of 
appropriate footwear and of podiatry services. 
Some studies have reported a symptomatic deterioration in the lower limbs that correlates 
with falls in blood pressure. Therefore, care should be taken to avoid excessive 
ultrafiltration in diabetic patients undergoing dialysis. In type 2 diabetics, better glycaemic 
control is associated with fewer amputations. 
The treatment of this condition requires a multidisciplinary approach, ideally in a combined 
clinic with a nephrologist, diabetologist, and a podiatrist. At the first sign of lower limb 
ischaemia, patients should be assessed by a vascular surgeon. 
7.2 Hyperparathyroidism 
Diabetics undergoing dialysis developed secondary hyperparathyroidism at a slower rate 
than nondiabetics and this may predispose to adynamic bone disease in which there is a 
reduced rate of bone turnover without an excess of unmineralized osteoid. The reduced 
bone formation may lead to enhanced deposition of aluminium at the ossification front. 
Diabetics appear to accumulate aluminium more readily and are more susceptible to bone 
pain and fractures related to aluminium bone disease, which may also be unmasked by 
parathyroidectomy. 
The diabetic uraemic should be treated with calcium-containing phosphate binders, which 
are ingested with every meal (500–1000 mg according to the amount of food). Aluminium-
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containing phosphate binders should be avoided because of possible aluminium intoxication. 
Vitamin D supplementation (e.g. 10000 U 25-(OH) vitamin D3 once weekly) is recommended. 
Serumphosphate control is important not only to prevent renal bone disease, but to prevent 
stiffness of the large arterial vessels. Increased stiffness of the aorta (36) is associated with 
reduced survival in end-stage renal disease and vascular stiffness is correlated with the 
increase in serumphosphate. 
8. Peritoneal dialysis (PD) 
8.1 Continuous ambulatory peritoneal dialysis (CAPD), continuous cycling peritoneal 
dialysis (CCPD), in diabetic patients 
CAPD has both medical and social benefits and most patients with diabetes are eligible for 
it. This technique enable patients to stay at home, where they can rapidly be taught the 
home dialysis regime and allows flexibility in treatment. The medical benefits of CAPD 
include slow and sustained ultrafiltration and a relative absence of rapid fluid and 
electrolyte changes and preservation of residual renal function. 
 
Parameters Peritoneal dialysis Haemodialysis
Advantages Disadvantages Advantages Disadvantages 
Technique Peritoneal 
access is easy 
Low technique 
survival rate, 
high 
hospitalization 
rate, higher rate 
of infection 
Better technique 
survival rate, 
lower 
hospitalization 
rate, lower 
infection rate 
Difficulty with 
vascular access 
Blood 
pressure 
Good blood 
pressure control, 
slow 
ultrafiltration 
and fewer 
episodes of 
cardiovascular 
instability 
– – Difficult blood 
pressure control, 
frequent 
hypotensive  
episodes 
Biochemical 
parameters 
Steady-state 
biochemical 
parameters, 
preservation of 
residual renal 
function for longer
– Efficient 
solute and water 
extraction 
– 
Social factors Maintains 
independence 
– Can be performed 
at home 
– 
Nutritional 
factors 
Fewer dietary 
restrictions 
Excessive weight
gain, poor 
nutrition, 
hyperlipidemia 
– Difficulty with 
fluid and dietary 
restrictions 
Table 5. Comparison of dialysis options for the diabetic patient (37, 38) 
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In CAPD the major osmotic agent for water removal is glucose. It is therefore of note to 
consider an extra amount of glucose (approximately 600–800 kcal) per treatment-day in the 
uraemic diabetic. Insulin dosage has to be adjusted. 
Some authors propose that insulin be administred via the CAPD fluid. This route of 
application is not without difficulties, because adsorption of insulin into the CAPD bag and 
possible infection by installation of insulin into the bag are possible.  
In table 6 are given a comparison of dialysis options for the diabetic patient. 
8.2 Assessing the quality of dialysis in CAPD 
Adequacy of dialysis is an important issue in CAPD as well as in HD. According to the 
DOQI guidelines, which are based on numerous studies (37), a weekly Kt/V of 2 or even 
more (weekly peritoneal creatinine clearance of more than 70 l) is nowadays considered an 
adequate dose of dialysis. In most patients this is only achievable when a certain amount of 
peritoneal fluid (more than 50 l/week) and a considerable residual renal function are 
combined. This has two implications: a) CAPD in diabetic patients should be started early 
(as in haemodialysis, at a creatinine clearance of approximately 20 ml/min); and b) residual 
renal function has to be monitored vigorously. If there is substantial fall in residual renal 
function (below 5 ml/min), in many cases adequate peritoneal dialysis is impossible. 
Inadequate PD, has a high mortality rate and patients must be taken off PD and either 
transferred to HD or, if possible, transplanted. 
8.3 Outcome of patients on PD (CAPD / CCPD) 
CAPD / CCPD appears to be associated in different evaluations with different outcomes in 
diabetics. The data from the United States Renal Data System (USRDS) registry indicate that, 
within the first 2 years of therapy, outcomes were superior to those for patients on HD. The 
risk of all-cause death for female diabetics aged >55 years in contrast, was 1.21 (confidence 
interval 1.17–1.24) for CAPD / CCPD, and in cause-specific analyses, these patients had a 
significantly higher risk of infectious death (39). This was confirmed by data from the 
Lombardy Registry but interpreted as a result of a hidden negative selection of patients (40). 
In a single-centre evaluation, HD and PD patients had similar survival, whereas the elderly 
(> 75 years) had a better survival on CAPD (41). Data from a Canadian Registry did not 
show any difference between the modalities, but a better survival for patients on PD (42). 
These discrepancies relate most probably to differences in clinical and demographic setting, 
patient populations, study design, statistical methods, and interactions between the dialytic 
modality effect and various other covariables. 
8.4 Renal and pancreas transplantation 
Renal transplantation is a safe and effective treatment modality for diabetic subjects with 
ESRD. Studies have shown that besides the improvement in quality of life, there is also 
posttransplantation better survival in uraemic patients (43, 44, 45). Simultaneous pancreas 
and kidney transplantation can be recommended as it prolongs survival in patients with 
diabetes and end-stage renal failure (46, 47) compared with kidney transplantation alone. In 
another series, patient or graft survival in diabetic patients receiving living-related donor 
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kidney transplants or simultaneous pancreas and kidney transplants were not different, 
whereas unadjusted graft and patient survival rates in diabetic recipients (older and longer 
on dialysis) of cadaveric renal transplant were significantly lower than in the other group 
(48). 
Despite these encouraging data, acturarial patient survival post-transplant is less favourable 
in diabetes compared to other primary renal diseases. It is indispensable to examine a 
diabetic uraemic thoroughly for vascular complications and infectious foci before the patient 
qualifies for the transplant waiting list (49). 
Living related donor graft survival is superior to cadaveric donor grafts in diabetics (80 
versus 64%, 5-year survival) as in nondiabetics. The higher mortality rate seen in cadaveric 
graft recipients is probably a consequence of a higher cumulative burden of 
immunosuppression and co-morbidities (50, 51). The introduction of improved 
immunosuppressive agents should further improve patient and graft survival both in the 
diabetic and nondiabetic population. 
Survival of the diabetic patient ranges from 45 to 75% at 5 years. This is significantly lower 
than in nondiabetic renal transplant recipients and is a consequence of cardiovascular 
disease: 36% of diabetic transplant recipients die from cardiovascular disease (51, 52). There 
is also an increased risk of death from infection, cerebrovascular disease, and peripheral 
vascular disease compared with nondiabetic graft recipients. The pretransplant presence of 
any vascular disease is reported to have a significant effect on mortality in diabetis 
transplant recipients, especially preexisting cardiac or peripheral vascular disease. Although 
patient survival is still suboptimal compared with nondiabetic subjects, it is better than that 
seen with dialysis. Transplantation is also associated with improved rehabilitation and a 
better quality of life than dialysis. 
8.5 Pretransplant assessment 
Most important is the vascular tree evaluation, the Achilles’ heel of every successful 
transplantation procedure. Careful evaluation of pelvic and lower extremily arteries must be 
performed. Non-invasive methods (e.g. Doppler and Duplex techniques) as well as invasive 
procedures (e.g. angiography) may be applied. Plain radiography on the pelvis documents 
the magnitude of media calcification in the uraemic diabetic. 
Coronary artery disease is an important issue in diabetic patients on dialysis. Non-invasive 
testing is often non substantial and coronary angiography is still the most helpful procedure 
to rule out severe coronary stenosis in this patient population. 
Additional information on cardiac valves are no less important, since aortic stenosis is a 
common problem in dialysis patients. 
Before transplantation, peripheral vascular surgery is mandatory, particularly on the 
ipsilateral side of the graft, to avoid post-transplant circulatory complications of the lower 
extremities. 
Cardiac surgery (bypass or valve replacement) is nowadays a common procedure in non-
diabetic and diabetic patients with an in-hospital mortality rate of 5.4%, which is roughly 
comparable to those of non-uraemic cardiac patients. 
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Chronic infections are common in diabetic patients and several sites of infections in diabetic 
patients have to be considered. Infection of the native kidneys may be due to renal calculi or 
papillary necrosis and secondary obstruction, and infection of the bladder is often due to 
multiresistant bacteria. 
Cholecystolithiasis is common in diabetics and recurrent cholecystitis should be an 
indication for cholecystectomy. Uraemic patients often suffer from chronic constipation and 
colonic diverticula are common in female diabetic patients, gynaecological infections or 
tumours must be excluded by bacteriological work-up and cytology. 
9. Post-transplantation in diabetics 
9.1 Hypertension 
Approximately 80–90% of adult renal transplant recipients develop hypertension post-
transplantation (52, 53). This incidence is no different in diabetics. Hypertension is a major 
risk factor for post-transplant cardiovascular disease and should be very well controlled in 
the diabetic. 
9.2 Hyperlipidemia 
Hypercholesterolaemia and hypertriglyceridaemia following renal transplantation have 
been reported. Increased total serum cholesterol is usually from increases in low-density 
lipoprotein (LDL) cholesterol (74% of patients) (53.) Many patients also have elevated levels 
of triglyceride (29%) and very low-density lipoprotein (VLDL) cholesterol, especially in the 
presence of proteinuria and graft dysfunction. High density lipoprotein (HDL) cholesterol 
levels are normal or may be reduced in up to 10% of transplant recipients and the 
composition of HDL may be abnormal, leading to a reduced cardioprotective effect. The use 
of diet and pharmacologic approaches to treat hyperlipidemia is reasonable. 
9.3 Infection 
Diabetics are at increased risk of infection following transplantation. As well as the effects of 
immunosuppression, which are similar to those in nondiabetic patients, factors specific to 
diabetics include impaired chemotaxis, increased colonization, and the effects of 
hyperglycaemia on host defences. Cell-mediated immunity is essentially normal in 
diabetics. Diabetics are at increased risk of foot infections and fungal infections, especially 
candidiasis and mucormycosis. Urinary tract infections are more common in diabetic 
transplant recipients and often associated with glycosuria and urinary stasis as a result of 
poor bladder emptying. In this situation, antibiotic prophylaxis is often required. 
9.4 Diabetic control and continuing complication of diabetes 
Glycaemic control remains an important post-transplantation factor affecting the 
development of macrovascular disease and the development of recurrent disease. A number 
of factors result in altered blood glucose homeostasis. Corticosteroid therapy and 
cyclosporin (cyclosporin A) alter blood glucose control and insulin requirements. 
Cyclosporine and, particularly, tacrolimus may lead to de novo diabetes. Improved renal 
clearances may also change post-transplantation insulin requirements. 
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9.5 Recurrent diabetic nephropathy 
Lesions consistent with diabetic nephropathy develop in almost all grafts, with basement 
membrane thickening and mesangial expansion reported after 2 years and hyalinization of 
arterioles after 4 years. The development of nodular glomerulosclerosis is, however, rare in 
the transplant. 
 
Factor  Peritoneal Dialysis  Haemodialysis Kidney Transplant 
Extensive 
Extrarenal 
disease 
No limitation No limitation except 
for hypertension 
 
Excluded in 
cardiovascular 
Insufficiency 
Geriatric patients No limitation No limitation Arbitrary exclusion 
as determined by 
programme 
Complete 
Rehabilitation 
Rare, if ever Very few individuals Common so long as 
graft functions 
Death rate Much higher than for 
nondiabetics 
Much higher than for
nondiabetics 
About the same as 
nondiabetics 
First year survival About 75% About 75% > 90% 
Survival to second 
decade 
Almost never Fewer than 5% About 1 in 5 
Progression 
of complications 
Usual and unremitting. 
Hyperglycaemia and 
hyperlipidemia 
accentuated 
Usual and 
unremitting. 
May benefit from 
metabolic control. 
Interdicted by 
functioning 
pancreas + kidney. 
Partially 
ameliorated by 
correction of 
azotemia. 
Special advantage Can be self-performed. 
Avoids swings in 
solute and intravascular
volume level. 
Can be self-
performed. 
Efficient 
extraction of solute 
and water in hours. 
Cures uraemia. 
Freedom to travel. 
Disadvantage Peritonitis. 
Hyperinsulenemia. 
Long hours of 
treatment. 
More days hospitalized 
than either 
hemodialysis or 
transplant. 
Blood access a 
hazard for clotting, 
haemorrhage and 
infection. 
Cyclical hypotension,
weakness. 
Aluminium toxicity, 
amyloidosis. 
Cosmetic 
disfigurement, 
hypertension, 
personal 
expense for 
cytotoxic 
malignacy. 
HIV transmission. 
Patient 
acceptance 
Variable, usual 
compliance with 
passive tolerance for 
regimen. 
Variable, often 
noncompliant 
with dietary, 
metabolic, or 
antihypertensive 
Enthusiastic during 
periods of good 
renal 
allograft function. 
Exalted when 
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component 
of regimen. 
pancreas 
proffers 
euglycaemia. 
Bias 
in comparison 
Delivered as first 
choice by enthusiasts 
though emerging 
evidence indicates 
substantially higher 
mortality than for 
haemodialysis 
Treatment by default.
Often complicated by
in attention to 
progressive cardiac 
and peripheral 
vascular disease. 
All kidney 
transplant 
programme 
preselect 
those patients with 
fewest 
complications. 
Exclusion 
of those older than 
45 for 
pancreas + kidney 
simultaneous 
grafting 
obviously 
favoruably 
prejudices 
outcome. 
Relative cost Most expensive over 
long run 
Less expensive than 
kidney transplant in 
first year, subsequent
years more 
expensive. 
Pancreas + kidney 
engraftment most 
expensive uraemia 
therapy for 
diabetic. 
After first year, 
kidney 
transplant C alone 
C 
lowest cost option. 
Table 6. Comparison of ESRD options for diabetic patients 
10. The future 
In the future, new techniques such as insulin gene manipulation in autologous cells (e.g. 
myoblasts, hepatocytes or fibroblasts) or islet cell transplantation will be the procedure of 
choice. Such a graft is currently technically feasible in patients who are recipients of other, 
usually renal, grafts. Another possibility is to graft encapsulated xeno-islets, protected 
against immune attack by encapsulation in a biocompatible membrane. 
Comparison of ESRD options for diabetics patients are given in table 6 (54). 
11. Diabetics on dialysis in the Republic of Macedonia 
Today the nephrologists are challenged both to control the underlying diabetic disease and 
also to provide an adequate renal replacement therapy. On the other hand, it has to be 
stressed that treatment of these patients and DM complications is very expensive. For 
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example, in USA the cost of treatment of these patients per year was estimated to about 100 
billion dollars, which is more than the whole health budget of a country like Italy (health 
budget estimated for 2001). Moreover, in USA around 2 billion dollars are being spent on 
dialysis treatments [55]. Recently performed, large epidemiological studies have 
demonstrated that CV morbidity and all cause mortality can be reduced with strict 
glycaemic and blood pressure control and with the use of anti-angiotensine agents and also 
lipid lowering agents [56-60]. Certain factors like age, time on dialysis, vascular access 
complications, co morbidities, type of dialysis membrane, time of dialysis and others have 
been identified to correlate with the survival of the patients on dialysis [61, 62]. These factors 
assume even greater importance in diabetics. Biocompatible membranes, ultrapure dialysis 
fluid and diffuse - convective techniques have also been promoted to reduce cardiovascular 
instability [63, 64] and to minimize the injuries of the excessive oxidative stress inherent in 
uremia and the dialysis treatment.     
In Republic of Macedonia (RM) in last two decades there was an increase of number of 
diabetic patients. The number of patients with diabetic nephropathy progressing to the 
point of need for renal replacement therapy and renal transplantation is also increasing [65- 
67]. Given the fact of lack of data and valuable epidemiological studies in these patients, we 
performed a nation wide study with the aim of defining prevalence of these patients in RM, 
determining the standards of care in diabetics in term of methodological approach, dialysis 
and drug treatment and analysis of these patients on dialysis. The aim of the study was to 
make a closer observation in all dialysis centers in 2002 in the country and to compare data 
with those obtained 2006. 
11.1 Patients and methods 
Data were collected from medical histories of diabetic patients on dialysis in all dialysis 
centers in Republic of Macedonia by using a specially developed questionnaire for this 
purpose. Date of 31 December for 2002 and 2006 year was selected as a “critical day” for 
data collection. Besides demographic data (name, surname, sex, date of birth and 
profession), data for cigarette smoking and alcohol consuming were collected as well as type 
of diabetes (family history for diabetes, therapy, dose and type of the insulin intake, 
duration of diabetes and kidney disease), hypertension (family history, duration, therapy), 
other renal diseases including diabetic nephropathy, as well as laboratory findings (residual 
diuresis, blood glucose level, HbA1C, microalbuminuria, proteinuria, urea, creatinin blood 
level, creatinin clearance, thryglycerides (TG) blood level, cholesterol, HDL and LDL 
cholesterol, hepatitis B virus serological markers (HBs Ag, anti HBc-Ig G) , hepatitis C virus 
serological markers (anti HCV) and human imunodeficiency virus antibodies (anti-HIV); 
type of dialysis (bicarbonate or acetate); duration and frequency of dialysis sessions, 
medications used, hypoglycemic events, number of hospitalizations, complications: 
cardiovascular events (pectoral angina, heart attack, cerebrovascular insult), hypertension, 
peripherial vascular artheriopathy (diabetic foot), diabetic retinopathy, infection of the 
urinary system); cause of death – if patient died. The progression of other diabetic 
complications was obtained by roentgenograms, ECG, echocardiography and examination 
of eye fundus. Special attention was paid to data on vascular access (type of central venous 
catheter, A-V fistula, graft, complications on vascular accesses infection/thrombosis, other 
complications, as well as number of created vascular accesses). 
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Patients were treated according to the recommendations introduced by University 
Nephrology Clinic - Skopje, Faculty of Medicine, “Ss. Cyril and Methodius” University in 
Skopje, as a reference center for dialysis patients in Republic of Macedonia [68]. Duration of 
dialysis sessions was approximately three times four hours per week divided into three day 
sessions in same week. Low flux polysulphonic membranes, were used. Water was prepared 
by a reverse osmosis and blood flow in most of the cases was 250-280ml/min, whereas 
dialysis flow was usually 500 ml/min. Dialysis machines used were GAMBRO types AK 10, 
AK 100 and AK 95. There was no reuse of the dialysis filters. A low salt intake diet and 
malnutrition protective protein intake of 1gr/kg diet were recommended to all patients. 
11.2 Results  
Total number of dialysis patients in RM was 1114 and 1074 in 2002 and 2006 year, 
respectively (Figure 1, Table 7). There were 109 (9.78%) diabetic patients on dialysis, 60 
(55%) male and 49 (45%) female in 2002. A slight increase of diabetics was determined in 
2006, namely there were 115 (10.7%) diabetic patients on dialysis, 74 (64.35 %) male and 41 
(35.65%) female in 2006 year, as to compare with 2000 when total number of dialysis 
patients was 1010 and number of diabetics on dialysis was 103 (10.19%) [65, 66] (Figure 2). 
There was a difference in distribution of diabetics on dialysis trough different dialysis 
centers in RM for 2002 and 2006 year (Table 8 and Table 9), respectively. Diabetics on 
dialysis were from 3% in Veles, to 21 % in Kavadarci for 2002. Similar diversity was 
obtained in 2006:  from 2.43% in Skopje Military Hospital Dialysis Center to 22.07% in 
University Nephrology Clinic - Skopje. In 2002 most of the diabetics on dialysis (31 patients) 
were registered in University Nephrology Clinic - Skopje and in the Nephrology Institute - 
Struga (15 patients) similarly like 2006 when most of diabetics on dialysis (34 patients) were 
in University Nephrology Clinic - Skopje and in Nephrology Institute - Struga (16 patients). 
The mean age of all diabetics on dialysis in 2002 was 58±10.29 years (56±10.49 for males and 
60±9.56 for females), and in all diabetics on dialysis in 2006 it was 56.5±10.71 years 
(55.06±8.82 for males and 57.92±12.56 for females) (Table 1). In 2002, 19 (17.43%) patients 
had DM1, while 90 (82.57%) patients had DM2. 28 (25.68%) patients were treated with oral 
anti-diabetic drugs and 62 (57.21%) patients were on insulin. In 2006, 15 (13.04%) patients 
had DM1 while 100 (86.96%) patients had DM2. 31 (26,96 %) of diabetics were treated with 
oral anti-diabetic drugs and 69 (60%) were on insulin. The mean age of DM1 patients in 2002 
was 47±11.6 years, with a diabetic history of 16.2±9.7 years, while the mean age of DM1 
patients in 2006 was 45±7.32 years, with a diabetic history of 24.07±11.07 years. The mean 
age of DM2 patients in 2002 was 60.37±8.33 with a diabetic history of 13.4±8.1 years and the 
mean age of DM2 patients in 2006 was 61.14±10.23 years with a diabetic history of 
14.18±8.42 (Table 1). The mean dose of insulin intake was 9.5±6.63IU and 10.85±9.29IU, for 
2002 and 2006 respectively. In 2002, 21% of diabetics on dialysis were smokers, 13% 
consumed alcohol, while 15% were engaged in sport, as compared to 2006 when 17.39% of 
diabetics on dialysis were smokers, 5.22% consumed alcohol and 3.48% were doing sport.  
The mean duration of dialysis therapy in 2002 for DM type 1 patients was 54.3±44.4 months, 
whereas in DM type 2 was 34.3±36.3 months. The mean duration of dialysis therapy in 2006 
for DM 1 patients was 76.29±74.96 months, whereas in DM 2 was 33.68±43.24. The mean 
body mass index (BMI) in 2002 was 26.4±3.28  kg/m2 and 25.5±2.92 kg/m2 in DM1 and DM2 
patients, respectively. In 2006 BMI was 23.49±4.74 kg/m2 and 24.77±3.70 kg/m2 in DM1 and 
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DM2 patients, respectively. There was a need for urgent dialysis treatment and a first 
dialysis session a trough femoral venous catheter in 90.1% and 94.4% of diabetics on dialysis 
in 2002 and 2006, respectively.  After a period of patient adaptation to dialysis procedure 
and in order to eliminate possible bacterial infection trough the femoral venous catheter, an 
arterio venous fistula (AVF) was created as a permanent vascular access for dialysis. 
Preventive AVF was created in 9.9% and in 5.6% of diabetics on dialysis in 2002 and 2006 
respectively. Thrombosis of the newly created AVF was detected in 41% and 24.35% in 2002 
and 2006 respectively, whereas AVF infection was detected in 58.6% of the patients in 2002. 
In 2002 there were 19.26% of patients on acetate dialysis and 80.74% on bicarbonate dialysis 
while in 2006 there were no patients on acetate dialysis, and all 110 diabetic patients 
(95.65%) were on bicarbonate dialysis modality (Figure 3). 
It has to be stressed that a high rate of HCV infection was noticed in diabetics on dialysis, 
57% and 37.39% of these patients were anti HCV positive in 2002 and in 2006, respectively. 
81% and 86.09% of the patients were treated with erytropoethin in 2002 and 2006, 
respectively. In both years hypertension (HTA) was the most frequent co-morbid state: in 
2002, 91% diabetics on dialysis had a HTA before dialysis program and following the start of 
dialysis sessions 40.54% (Table 10). Furthermore, in 2006 HTA was registered in 47.74% of 
diabetics before dialysis, and in 60% of patients during dialysis. Finally, family history for 
HTA was noticed in 43% and 29.57% patients, in 2002 and 2006, respectively. The most 
frequent cardiovascular co-morbidity in these patients for the year 2002 and 2006 are shown 
in Table 10. 
 
Fig. 1. Total number of patients on dialysis and diabetics on dialysis. 
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 2002 year 2006 year 
N° dialysis patients 1114 1074 
N° of diabetics 109 (9.78%) 115 (10.7%) 
Male Pts 60 (55%) 74 (64.35%) 
Female Pts 49 (45%) 41 (35.65%) 
Mean age 58±10.29 56.5±10.71 
Mean age male 56±10.49 55.06±8.82 
Mean age female 60±9.56 57.92±12.56 
Patients with DM1 19 (17.43%) 15 (13.04%) 
Mean age DM1 47±11.6 45±7.32 
DM history DM1 (years) 16.2±9.7 24.07±11.7 
DM1 dialysis history (months) 54.3±44.4 76.29±74.96 
Patients with DM2 90 (82.57%) 100 (86.96%) 
Mean age DM2 60.4±8.33 61.14±10.23 
DM history DM2 (years) 13.4±8.1 14.18±8.42 
DM2 dialysis history (months) 34.3±36.3 33.68±43.24 
On OADD 28 (25.68%) 31 (26.96%) 
On insulin 62 (57.21%) 69 (60%) 
Dose of insulin (IU) 9.5±6.63 10.85±9.29 
BMI in DM1 kg/m2 26.4 25.5 
BMI in DM2 kg/m2 23.49±4.74 24.77±3.70 
First dialysis on FVC (%) 90.1 94.4 
Preventive AVF (%) 9.9 5.6 
Thrombosis of first AVF (%) 41 24.35 
Anti HCV positive (%) 57 37.39 
DM1 - Diabetes mellitus type 1, DM2 -  Diabetes mellitus type 2 ; OADD – Oral antidiabetic drugs ;  
BMI – Body mass index; FVC – femoral vascular cathether ; AVF – Arterio venouse fistula 
Table 7. Characteristics of diabetics on dialysis in Republic of Macedonia 
www.intechopen.com
 
Renal Failure – The Facts 
 
258 
 
Fig. 2. Oscillations in the total number of dialysis patients and diabetics on dialysis period 
2001 – 2006 in RM 
 
 Dialysis center N° of Dialysis pts N° of Diabetics % DM 
University Clinic of Nephrology, Skopje 201 31 15.42 
Institute of Nephrology, Struga 204 15 7.35 
Тetovo 63 9 14.28 
Gevgelija 28 1 3.57 
Debar 15 2 13.30 
Gostivar 53 4 7.54 
Ǹočani 24 3 12.50 
Kumanovo 60 6 10.00 
Delčevo 31 4 12.90 
Strumica 46 4 8.69 
Prilep 60 6 10.00 
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Bitola 38 4 10.52 
Štip 49 3 12.50 
Železara 125 5 4.00 
Military hospital, Skopje  40 3 7.5 
Veles 39 1 2.56 
Kavadarci 38 8 21.50 
 Total 1114 109 9.78 
Table 8. Distribution of dialysis patients by dialysis centers in RM, year 2002 
 
 Dialysis center N° of Dialysis pts N° of Diabetics % DM 
University Nephrology Clinic, Skopje 171 32 19.88 
Nephrology Institute, Struga 171 16 9,36 
Тetovo 69 11 15,94 
Gevgelija 30 2 6,67 
Ǹriva Palanka 26 3 11,54 
Gostivar 46 4 8,70 
Ǹočani 31 1 3,23 
Kumanovo 49 7 14,29 
Delčevo 32 7 21,88 
Strumica 47 3 6,38 
Prilep 56 6 10,71 
Bitola 43 2 4,65 
Štip 60 4 6,67 
Železara 162 12 7,41 
Military hospital 40 2 5 
Veles 41 1 2,44 
 Total 1074 115 10,71 
Table 9. Distribution of dialysis patients by dialysis centers in RM, year 2006 
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Fig. 3. Use of acetate and bicarbonate haemodialysis (HD) in 2002 and 2006 
 
Condition Before Dialysis 
(2002) 
During Dialysis 
(2002) 
Before Dialysis 
(2006) 
During Dialysis 
(2006) 
Pectoral angina 7.2% 19% 1.12% 3.4% 
Heart attack 5.4% 5.4% 1.12% 4.43% 
Intermitent 
claudication 
10% 10% 2.25% 11.3% 
Cerebrovascular 
attack 
7% 8% 8.7% 9.57% 
Hypertension 
(HTA) 
91% 40.54% 47.74% 60% 
Table 10. Distribution of the most frequent cardiovascular co-morbidity in diabetics on 
dialysis in 2002 and 2006. 
11.3 Discussion 
In the present analysis we have demonstrated an increase in the prevalence on diabetic 
dialysis patients in certain dialysis centers of RM. It has been reported before that the annual 
incidence of patients who initiate dialysis is constantly increasing in all industrialized 
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countries and a significant part of this increase is explained by the influx of diabetic patients 
on dialysis [68, 69]. This study shows the importance of the need to increase the number of 
specialists nephrologists in RM who will take an important role in healthcare of these 
patients in collaboration with endocrinologists and other specialists practitioners.  
We have previously shown that the number of diabetics on dialysis in RM enlarges slowly 
but progresively [65-68]. In current analysis, beside the fact that mean total prevalence of 
DM was just slightly increased as compared to our previous studies [66], we show that there 
is an important difference in prevalence of diabetics on dialysis between different dialysis 
centres. In certain dialysis in RM the prevalence of diabetics reached a level similar with that 
of Northern European countries [69] while in others it was lower than expected. This 
diversity in the number of diabetics on dialysis could be explained by the fact that RM is a 
developing country, geographically European with predominance of Mediterranean diet, 
and this difference could be due to a numerous economical, sociological, genetic, 
environmental and nutritional factors in different parts of the country.  
We included in the study all diabetic patients on dialysis in RM, without differentiating 
diabetics who started dialysis because of diabetic nephropathy from those who started 
dialysis with other renal pathology. We show that diabetics with CKD in most of the cases 
were diagnosed at the University Nephrology Clinic - Skopje, and diagnosis most often was 
in developed phase of CKD. It has been shown that these patients present an extraordinary 
acceleration of all clinical complications and it is a well known fact that accelerated 
development of terminal uraemia constitutes a devastating clinical event [1, 55, 69, 70, 71]. 
Phase of the disease when diabetes is installed is accompanied usually with a certain variety 
of cardiovascular complications, predominatelly as a result of a long-term hypertension, 
nephrotic syndrome and infections. Metabolic and blood vessels modifications induce 
constant overweight and problems with vascular access leading to quality of life decrease in 
these patents. Consequently, as it has been showen by the others and us, the survival rate 
of diabetics on dialysis is significantly reduced, Figure 4 [72, 73]. When compared with 
other dialisys patients it has been shown that the best survival rate was observed in those 
with balkan endemic nephropathy and adult polycystic kidney disease. This observation 
goes in line with other studies confirming that in diabetics on dialysis the quality of life is 
impaired and survival is significantly curtailed [1, 74, 26]. It has been shown also that the 
clinical results depend on both the severity of complications present at the initiation of 
dialysis and on capacity to slow its evolution during dialysis [74]. In current analysis we 
did not evaluate the effect of patient therapies on the incidence of complications and on 
patient mortality. 
Besides the fact that most of the nephrologists and internal medicine specialists in RM are 
aware of the importance of the timely initiation of dialysis for diabetic patients, this analysis 
underlines the fact that dialysis initiation often starts in emergency conditions and most of 
the patients start dialysis program at University Nephrology Clinic – Skopje trough urgently 
and temporary placed femoral venous catheter. We found that almost 90% of first dialysis 
sessions in 2002 as well as in 2006 were started in emergency conditions, confirming that 
diabetics are reffered to the nephrologists late in the course of CKD. Analysing why this 
happens, we think that a part of responsibility for the delay of dialysis initiation could be 
explained by patient mentality but it is also important to stress the important role of medical 
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personnel in preparing the patient for dialysis. We have to underline insufficient 
coordination between physicians such as general practitioners, internists, endocrinologists 
and nephrologists, and lack of their influence on patient dialysis reality acceptance. It is also 
important to notice that in two dialysis centres where the prevalence in diabetics on dialysis 
is much higher, dialysis patients are followed by educated and well trained nephrologists. 
In these centres accessibility of other specialties practitioners is higher as compared to 
dialysis centres where patients are followed by internal medicine specialists and other 
specialized doctors are also accessible. This might explain the high difference in number of 
diabetic’s among different dialysis centers and it also underlines the need for more trained 
nephrologists in the country and their more important implication in follow up of diabetics 
on dialysis.  
 
Fig. 4. Distribution of survival (Kaplan Meier test) of dialysis patients, distribution by basic 
renal disease (University Clinic of Nephrology - Skopje); abbrevations: Diabetes Mellitus 
Insulin Independent – DM1,  Diabetes Mellitus Insulin Dependent DM2, Arterial 
Hypertension – HTA, Malignant HTA – HTA mal., Adult Polycystic Renal Diseases-APKD, 
Balkan Endemic Nephropathy – BEN). 
It has been shown previously that a very large difference exists in the ratio of DM2 to DM1 
on dialyisis in different European countries and among different regions in a same country 
[1]. A recent study of Italian population showed that most diabetics on dialysis were DM2 
patients, probably because of high prevalence of this disease among the general population 
[75]. In our study we found that the ratio of DM2 to DM1 patients was approximately 4,3 : 1. 
As expected, patients with DM2 were older, with higher body weight and body mass index. 
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Epidemiological studies has also shown that cardiovascular morbidity and mortality can be 
reduced with pharmacological therapy that normalizes blood pressure values and controls 
hyperglicemia, hyperlipidemia, platelet agreggation and hypercoagulability [56-58]. 
Proportion of diabetics od dialysis treated with ACE inhibitors and / or angiotensin 
receptor blockers (ARB), beta blockers and antiplatelat drugs was still quite low as 
compared to propositions of the guidelines. There was a negligible number of patients 
treated with lipid lowering agents.  
In conclusion, the present study underline the importance of an interdisciplinary 
approach in early diagnosis and treatment of diabetes, diabetic nephropathy and 
treatment of diabetics on dialysis, as well as importance of introducting preventive 
measures for progression of CKD in these patients. In most dialysis centres in the 
Republic of Macedonia prevalence of diabetics on dialysis did not increase in the period 
from 2002 to 2006 where these patients were followed mostly by internal medicine 
specialists. Frequency of complications was increased in DM2 compared to DM1 dialysis 
patients. Blood glucose level control is important as well as a strict control of the blood 
preasure. Bicarbonate dialysis is a dialysis of choice with an optimal duration of 
minimun 12 hours per week. More nephrologists need to be involved in the dialysis 
centres and together with an improvement of colaboration between general practitioners, 
internternal medicine doctors, endocrinologists, nephrologists, cardiologists, 
ophtalmologists, neurologists in order to improve health care for these patients. This 
kind of studies should be carried out on a regular basis in Republic of Macedonia. 
12. Could we prevent or postpone diabetic kidney disease and development 
of chronic renal failure? 
The World Kidney Day, 11 March 2010 was devoted to diabetic kidney disease, under the 
auspices of the International Society of Nephrology (ISN) and the International Federation 
of Kidney Foundations (IFKF), together with the International Diabetic Federation (IDF).  
R.C. Atkins and P. Zimmet in their paper: Diabetic kidney disease: act now or pay later [76] 
point out the importance of a better understanding of the global pandemic of type 2 diabetes 
and diabetic kidney disease. They suggest that it is necessary to alert governments, health 
organizations, providers, doctors and patients to the increasing health and socioeconomic 
problems due to diabetic kidney disease and its sequels: end-stage kidney disease requiring 
dialysis, and cardiovascular death. It should be emphasized that its management involves 
prevention, recognition and treatment of its complications. 
The most important measure is primary prevention of type 2 diabetes. It will require 
massive lifestyle changes in the developing world, supported by strong governmental 
commitment to promote lifestyle and societal change. 
In the Republic of Macedonia there are about 100,000 patients with diabetes mellitus type 1 
and 2; 85–95% have diabetes mellitus type 2. Around 28,000–30,000 patients are on therapy 
with insulin. 
Some of them are candidates for development of diabetic kidney disease. 
We should develop a strategy to detect early diabetic kidney disease by screening for 
albuminuria as well as reduced glomerular filtration rate. It is very important to introduce 
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public education about the relationship between diabetes and kidney disease. There is a 
remarkable lack of awareness among patients about their condition. 
In our papers: Chronic Kidney Disease: a Hidden Epidemic [77] and Public Health Aspects of Renal 
Disease in the Republic of Macedonia 1983–2007 [78] we have shown a continuous increase in 
end-stage renal disease and renal replacement therapy (RRT) in the Republic of Macedonia. 
In 2002, we had 1,056 patients on RRT compared to 1,216 in 2005. In some dialysis centres 
20% of the patients on haemodialysis are diabetics. Our message was that there is an urgent 
need for a screening programme for the detection of Chronic Kidney Disease (CKD) in the 
Republic of Macedonia. Health authorities, nephrologists and general physicians should 
collaborate on the detection of CKD. 
“There is evidence that early therapeutic intervention in patients with chronic kidney 
disease or diabetes can delay the onset of complications and improve outcomes. For 
example, the UKPDS [79, 80], STENO-2 [81] and ADVANCE studies [82, 83, 84] all 
demonstrated that tight control of blood glucose level and blood pressure (and lipids in 
STENO-2) significantly reduced the incidence and progression of diabetic kidney disease. In 
people with type 2 diabetes, inhibition of the renin-angiotensin-aldosterone system using an 
angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) 
decreased the progression from normoalbuminuria to microalbuminuria [85] and slowed 
the development of ESRD [86]. Thus the use of an ACE inhibitor or ARB is now standard 
therapy for patients with diabetic nephropathy, as well as glucose, lipid and blood pressure 
control.” [76] 
12.1 How should we act now? 
We are going to repeat our message from 2008 [77]: “there is an urgent need for a screening 
programme for the detection of CKD” and we will add as well as of diabetic kidney disease 
in the Republic of Macedonia. 
We can follow the steps suggested by Atkins and Zimmet (76): 
“i.  prevention of type 2 diabetes; 
ii. screening for early diabetic kidney disease; 
iii. increasing patient awareness of kidney disease; 
iv. using medications of proven strategy” 
"The ultimate challenge is to get action from primary health care to all higher levels, from 
the individual patient, to those at risk, in various health jurisdictions, in all countries despite 
varying economic circumstances and priorities. The problem is a global one and yet requires 
action at a local level; prevention screening and treatment strategies; education, including 
increasing awareness both in diabetic patients and those at risk of developing diabetes; and 
health priorities and governments. Basic research and clinical trials searching for a new 
understanding and therapies must be supported." [76] 
In our country we should work harder on the prevention of diabetic kidney diseases, to stop 
or postpone the development of CKD and chronic renal failure with modern therapy and 
the need for RRT. 
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encounter a nephrological problems in their day-to-day practice.
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